Slate Path Capital LP 13D and 13G filings for Cyclerion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-13 4:30 pm Unchanged | 2022-11-01 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.500% | 0 (Unchanged) | Filing |
| 2022-10-21 5:13 pm Unchanged | 2022-10-21 | 13D | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.500% | 0 (Unchanged) | Filing |
| 2022-02-11 4:41 pm Purchase | 2021-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 357,880 16.490% | 48,077 (+15.52%) | Filing |
| 2020-08-10 4:16 pm Purchase | 2020-07-31 | 13G | Cyclerion Therapeutics, Inc. CYCN | Slate Path Capital LP | 309,803 18.300% | 309,803 (New Position) | Filing |